scholarly journals Interstitial Fluid Lung Disease (IFLD) of the Interstitium Organ the Cause and Self-Care to a Self-Cure for Lung Disease

2020 ◽  
Vol 5 (1) ◽  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Fluid ◽  
Self Care ◽  
Air Sacs ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Interstitial lung disease (IFLD), or diffuse parenchymal lung disease (DPLD), is a group of lung diseases affecting the Interstitium (the interstitial fluids or space around the alveoli (air sacs of the lungs) [1,2].

scholarly journals Systemic sclerosis-associated interstitial lung disease: review of the literature

2020 ◽  
Vol 28 (4) ◽  
pp. 59-71
Author(s):  
Rositsa Svetoslavova Dacheva ◽  
Simeon Valentinov Monov
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Review Of The Literature ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Абстракт: Прогресивната системна склероза (Systemic sclerosis, SSc) представлява системно заболяване на съединителната тъкан, характеризиращо се с фиброзни промени, засягащи кожата и вътрешните органи, васкулопатия и имунна дисрегулация. Интерстициалните пневмонии представляват група дифузни паренхимни белодробни болести (diffuse parenchymal lung disease – ДПББ), или още наричани интерстициални белодробни болести, ИББ (interstitial lung diseases – ILD). ИББ е водещо усложнение на SSc и е водеща причина за смъртност при пациенти със SSc. Патогенезата на белодробното увреждане включва три основни процеса - персистираща увреда на еднотелните клетки, активация на имунната система и активация на фибробласти, водещо до акумулация на екстрацелуларен матрикс и тъканна увреда. Необходим е комплексен подход за правилно диганостициране и избор на терапия.

Diffuse parenchymal lung disease: An introduction

2020 ◽  
pp. 4166-4176
Author(s):  
F. Teo ◽  
A.U. Wells
Keyword(s):  
Lung Disease ◽  
Lung Diseases ◽  
Pulmonary Function Tests ◽  
Diagnostic Algorithm ◽  
Clinical History ◽  
Logical Sequence ◽  
Diffuse Parenchymal Lung Disease ◽  
Granulomatous Diseases ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

The nomenclature of diffuse parenchymal lung disease (also known as interstitial lung disease) has caused a great deal of confusion, with use of complicated histopathological terms not always corresponding to clinico-radiological entities. Five major groupings are now recognized: idiopathic interstitial pneumonias; diseases associated with systemic conditions, including rheumatological disorders; diseases caused by environmental triggers or drugs; granulomatous diseases; and other diffuse lung diseases. Classification is based on recognition of clinical, radiological, and histopathological patterns, as opposed to the purely histopathological terminology. Diagnosis is complicated by the large number of disorders grouped within the diffuse parenchymal lung diseases. A systematic diagnostic algorithm, based upon careful clinical evaluation and a logical sequence of tests, is essential. Clinical history, clinical examination, chest radiography, pulmonary function tests, and selective blood tests should be followed by high-resolution CT, bronchoalveolar lavage (in some cases), and lung biopsy (in a few cases).

Five simple reasons to discard DIP, or why we should stop calling dolphins big fish

2020 ◽  
Vol 73 (11) ◽  
pp. 762-768 ◽  
Author(s):  
Sanjay Mukhopadhyay ◽  
Scott W Aesif ◽  
Irene Sansano
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Interstitial Pneumonia ◽  
Lung Diseases ◽  
Modern Concept ◽  
Lung Abnormalities ◽  
Never Smokers ◽  
The Relationship ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

The aim of this review is to explain why the term ‘desquamative interstitial pneumonia’ (DIP) should be discarded and replaced with modern terminology. Reason 1: DIP is a misnomer. Within a few years after the term was coined, it was shown that the airspace cells in DIP are macrophages not desquamated pneumocytes. Reason 2: As a result of overly simplistic and poorly defined histologic criteria, DIP is currently a mixed bag of smoking-related diseases and unrelated processes in never-smokers. Reason 3: DIP obfuscates the modern concept that smoking causes some forms of parenchymal lung disease. Despite the fact that >80% of cases of DIP are caused by smoking, it is currently classified as a ‘smoking-related idiopathic interstitial pneumonia’, an oxymoron. Reason 4: The premise that the presence of numerous macrophages within airspaces defines an entity creates problematic histologic overlap with other lung diseases that may feature prominent airspace macrophages. Reason 5: DIP is outdated. It was coined in 1965, when many entities in interstitial lung disease had not been described, smoking-related interstitial lung disease was an unknown concept, computed tomograms of the chest had not been introduced and immunohistochemistry was unavailable. We suggest a way forward, which includes eliminating the term DIP and separating smoking-related lung abnormalities (including accumulation of pigmented airspace macrophages) from cases characterised by numerous non-pigmented macrophages in never-smokers. The laudable goal of smoking cessation is not served well by muddying the relationship between smoking and lung disease with inaccurate, outdated terminology.

scholarly journals Research highlights from the 2018 ERS International Congress: interstitial lung diseases

2019 ◽  
Vol 5 (1) ◽  
pp. 00215-2018 ◽  
Author(s):  
Tiago M. Alfaro ◽  
Catharina C. Moor ◽  
Veronica Alfieri ◽  
Florence Jeny ◽  
Michael Kreuter ◽  
...  
Keyword(s):  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
International Congress ◽  
European Respiratory Society ◽  
Diffuse Parenchymal Lung Disease ◽  
Origin Group ◽  
Parenchymal Lung Disease ◽  
Selection Of ◽  
Parenchymal Lung

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

ProSP-B as a potential biomarker in diffuse parenchymal lung disease (DPLD)

Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
N Kahn ◽  
A Rossler ◽  
K Hornemann ◽  
T Muley ◽  
A Warth ◽  
...  
Keyword(s):  
Lung Disease ◽  
Potential Biomarker ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

scholarly journals Categorizing diffuse parenchymal lung disease in children

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Matthias Griese ◽  
Armin Irnstetter ◽  
Meike Hengst ◽  
Helen Burmester ◽  
Felicitas Nagel ◽  
...  
Keyword(s):  
Lung Disease ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung
Sign in / Sign up

Export Citation Format

Share Document